Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study

Circulation

Volumn 132, Issue 15, 2015, Pages 1395-1403

  Deftereos, Spyridon ^a,b   Giannopoulos, Georgios ^a,b   Angelidis, Christos ^a   Alexopoulos, Nikolaos ^a   Filippatos, Gerasimos ^b   Papoutsidakis, Nikolaos ^c   Sianos, George ^d   Goudevenos, John ^e   Alexopoulos, Dimitrios ^f   Pyrgakis, Vlasios ^a   Cleman, Michael W ^g   Manolis, Antonis S ^b   Tousoulis, Dimitrios ^b   Lekakis, John ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Athens Euroclinic   (Greece)

^d AHEPA UNIVERSITY HOSPITAL   (Greece)

^e UNIVERSITY OF IOANNINA   (Greece)

^f UNIVERSITY OF PATRAS   (Greece)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

area under curve; creatine kinase; gadolinium; magnetic resonance imaging; MB form; neutrophil; troponin T

Indexed keywords

COLCHICINE; CREATINE KINASE MB; PLACEBO; BIOLOGICAL MARKER; C REACTIVE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART INFARCTION SIZE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN; TREATMENT DURATION; AREA UNDER THE CURVE; BLOOD; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; HEART MUSCLE; MIDDLE AGED; MYOCARDIAL INFARCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROSPECTIVE STUDY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOMARKERS; C-REACTIVE PROTEIN; COLCHICINE; CREATINE KINASE, MB FORM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 84944104676     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.017611     Document Type: Article

References (47)

1. Braunwald E, Kloner RA, Myocardial reperfusion: A double-edged sword? J Clin Invest 1985 76 1713 1719. doi: 10.1172/JCI112160
2. Entman ML, Michael L, Rossen RD, Dreyer WJ, Anderson DC, Taylor AA, Smith CW, Inflammation in the course of early myocardial ischemia. FASEB J 1991 5 2529 2537
3. Turer AT, Hill JA, Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol 2010 106 360 368. doi: 10.1016/j.amjcard.2010.03.032
4. Christia P, Frangogiannis NG, Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest 2013 43 986 995. doi: 10.1111/eci.12118
5. Ross R, Atherosclerosis is an inflammatory disease. Am Heart J 1999 138 5 pt 2 S419 S420
6. Klingenberg R, Luscher TF, Inflammation in coronary artery disease and acute myocardial infarction-is the stage set for novel therapies? Curr Pharm Des 2012 18 4358 4369
7. Fitzgerald GA, Coxibs and cardiovascular disease. N Engl J Med 2004 351 1709 1711. doi: 10.1056/NEJMp048288
8. Nussinovitch U, de Carvalho JF, Pereira RM, Shoenfeld Y, Glucocorticoids and the cardiovascular system: state of the art. Curr Pharm Des 2010 16 3574 3585
9. Olsen AM, Fosbøl EL, Lindhardsen J, Andersson C, Folke F, Nielsen MB, Køber L, Hansen PR, Torp-Pedersen C, Gislason GH, Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients-A nationwide study. PLoS One 2013 8 e54309. doi: 10.1371/journal.pone.0054309
10. Deftereos S, Giannopoulos G, Papoutsidakis N, Panagopoulou V, Kossyvakis C, Raisakis K, Cleman MW, Stefanadis C, Colchicine and the heart: pushing the envelope. J Am Coll Cardiol 2013 62 1817 1825. doi: 10.1016/j.jacc.2013.08.726
11. Jeffreys H, Jeffreys BS, Methods of Mathematical Physics 1988 3rd ed Cambridge, England Cambridge University Press 286 288
12. Heiberg E, Ugander M, Engblom H, Götberg M, Olivecrona GK, Erline D, Arheden H, Automated quantification of myocardial infarction from MR images by accounting for partial volume effects: Animal, phantom, and human study. Radiology 2008 246 581 588. doi: 10.1148/radiol.2461062164
13. Sadowski M, Ząbczyk M, Undas A, Coronary thrombus composition: links with inflammation, platelet and endothelial markers. Atherosclerosis 2014 237 555 561. doi: 10.1016/j.atherosclerosis.2014.10.020
14. Adlbrecht C, Wurm R, Humenberger M, Andreas M, Redwan B, Distelmaier K, Klappacher G, Lang IM, Peri-interventional endothelin-A receptor blockade improves long-term outcome in patients with ST-elevation acute myocardial infarction. Thromb Haemost 2014 112 176 182. doi: 10.1160/TH13-10-0832
15. Gomaraschi M, Ossoli A, Favari E, Adorni MP, Sinagra G, Cattin L, Veglia F, Bernini F, Franceschini G, Calabresi L, Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. Cardiovasc Res 2013 100 36 43. doi: 10.1093/cvr/cvt169
16. Mayyas FA, Al-Jarrah MI, Ibrahim KS, Alzoubi KH, Level and significance of plasma myeloperoxidase and the neutrophil to lymphocyte ratio in patients with coronary artery disease. Exp Ther Med 2014 8 1951 1957. doi: 10.3892/etm.2014.2034
17. Lipkova J, Parenica J, Duris K, Helanova K, Tomandl J, Kubkova L, Vasku A, Goldbergova Pavkova M, Association of circulating levels of RANTES and -403G/A promoter polymorphism to acute heart failure after STEMI and to cardiogenic shock. Clin Exp Med 2015 15 405 414. doi: 10.1007/s10238-014-0294-5
18. He J, Li J, Wang Y, Hao P, Hua Q, Neutrophil-to-lymphocyte ratio (NLR) predicts mortality and adverse-outcomes after ST-segment elevation myocardial infarction in Chinese people. Int J Clin Exp Pathol 2014 7 4045 4056
19. Sawant AC, Adhikari P, Narra SR, Srivatsa SS, Mills PK, Srivatsa SS, Neutrophil to lymphocyte ratio predicts short- and long-term mortality following revascularization therapy for ST elevation myocardial infarction. Cardiol J 2014 21 500 508. doi: 10.5603/CJ.a2013.0148
20. van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, Roe MT, Ezekowitz JA, Moliterno DJ, Neumann FJ, Reist C, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Granger CB, Theroux P, APEX AMI Investigators Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. Int J Cardiol 2013 168 2127 2133. doi: 10.1016/j.ijcard.2013.01.004
21. Lindberg S, Pedersen SH, Mogelvang R, Galatius S, Flyvbjerg A, Jensen JS, Bjerre M, Soluble form of membrane attack complex independently predicts mortality and cardiovascular events in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am Heart J 2012 164 786 792. doi: 10.1016/j.ahj.2012.08.018
22. Théroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB, Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the COMMA trial. Eur Heart J 2005 26 1964 1970. doi: 10.1093/eurheartj/ehi292
23. Guerchicoff A, Stone GW, Mehran R, Xu K, Nichols D, Claessen BE, Guagliumi G, Witzenbichler B, Henriques JP, Dangas GD, Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: results of the HORIZONS-AMI trial. Catheter Cardiovasc Interv 2015 85 335 342. doi: 10.1002/ccd.25620
24. Brunetti ND, Correale M, De Gennaro L, Cuculo A, Pellegrino PL, Di Biase M, Blunted inflammatory response in STEMI patients timely reperfused. J Cardiovasc Med (Hagerstown) 2014 15 48 52. doi: 10.2459/JCM.0b013e328365c13a
25. Urbano-Moral JA, Lopez-Haldon JE, Fernandez M, Mancha F, Sanchez A, Rodriguez-Puras MJ, Villa M, Lopez-Pardo F, Diaz de la Llera L, Valle JI, Martinez A, Prognostic value of different serum biomarkers for left ventricular remodelling after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart 2012 98 1153 1159. doi: 10.1136/heartjnl-2012-301636
26. van Diepen S, Roe MT, Lopes RD, Stebbins A, James S, Newby LK, Moliterno DJ, Neumann FJ, Ezekowitz JA, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Theroux P, Granger CB, Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. J Thromb Thrombolysis 2012 34 106 113. doi: 10.1007/s11239-012-0691-0
27. van der Laan AM, Hirsch A, Robbers LF, Nijveldt R, Lommerse I, Delewi R, van der Vleuten PA, Biemond BJ, Zwaginga JJ, van der Giessen WJ, Zijlstra F, van Rossum AC, Voermans C, van der Schoot CE, Piek JJ, A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: monocytes and myocardial infarction. Am Heart J 2012 163 57 65.e2. doi: 10.1016/j.ahj.2011.09.002
28. Husser O, Bodi V, Sanchis J, Nunez J, Mainar L, Chorro FJ, Lopez-Lereu MP, Monmeneu JV, Chaustre F, Forteza MJ, Trapero I, Dasi F, Benet I, Riegger GA, Llacer A, White blood cell subtypes after STEMI: temporal evolution, association with cardiovascular magnetic resonance-derived infarct size and impact on outcome. Inflammation 2011 34 73 84. doi: 10.1007/s10753-010-9209-0
29. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL, Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013 61 404 410. doi: 10.1016/j.jacc.2012.10.027
30. Deftereos S, Giannopoulos G, Panagopoulou V, Bouras G, Raisakis K, Kossyvakis C, Karageorgiou S, Papadimitriou C, Vastaki M, Kaoukis A, Angelidis C, Pagoni S, Pyrgakis V, Alexopoulos D, Manolis AS, Stefanadis C, Cleman MW, Anti-inflammatory treatment with colchicine in stable chronic heart failure: A prospective, randomized study. JACC Heart Fail 2014 2 131 137. doi: 10.1016/j.jchf.2013.11.006
31. Deftereos S, Giannopoulos G, Efremidis M, Kossyvakis C, Katsivas A, Panagopoulou V, Papadimitriou C, Karageorgiou S, Doudoumis K, Raisakis K, Kaoukis A, Alexopoulos D, Manolis AS, Stefanadis C, Cleman MW, Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life. Heart Rhythm 2014 11 620 628. doi: 10.1016/j.hrthm.2014.02.002
32. Nogales E, Whittaker M, Milligan RA, Downing KH, High-resolution model of the microtubule. Cell 1999 96 79 88
33. Downing KH, Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000 16 89 111. doi: 10.1146/annurev.cellbio.16.1.89
34. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M, Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004 428 198 202. doi: 10.1038/nature02393
35. Bhattacharyya B, Panda D, Gupta S, Banerjee M, Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 2008 28 155 183. doi: 10.1002/med.20097
36. Terkeltaub RA, Colchicine update: 2008. Semin Arthritis Rheum 2009 38 411 419. doi: 10.1016/j.semarthrit.2008.08.006
37. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G, Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995 96 994 1002. doi: 10.1172/JCI118147
38. Forrat R, Sebbag L, Ferrera R, Hadour G, Canet E, Tabib A, de Lorgeril M, Effect of colchicine on circulating and myocardial neutrophils and on infarct size in a canine model of ischemia and reperfusion. J Cardiovasc Pharmacol 1996 27 876 883
39. Raju NC, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW, Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: A pilot randomized controlled trial. J Thromb Thrombolysis 2012 33 88 94. doi: 10.1007/s11239-011-0637-y
40. Giannopoulos G, Angelidis C, Kouritas VK, Dedeilias P, Filippatos G, Cleman MW, Panagopoulou V, Siasos G, Tousoulis D, Lekakis J, Deftereos S, Usefulness of colchicine to reduce perioperative myocardial damage in patients who underwent on-pump coronary artery bypass grafting. Am J Cardiol 2015 115 1376 1381. doi: 10.1016/j.amjcard.2015.02.036
41. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC, Salloum FN, Hastillo A, Dinarello CA, Vetrovec GW, VCU-ART Investigators Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010 105 1371 1377.e1. doi: 10.1016/j.amjcard.2009.12.059
42. Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW, Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 2013 111 1394 1400. doi: 10.1016/j.amjcard.2013.01.287
43. Morton AC, Rothman AM, Greenwood JP, Gunn J, Chase A, Clarke B, Hall AS, Fox K, Foley C, Banya W, Wang D, Flather MD, Crossman DC, The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J 2015 36 377 384. doi: 10.1093/eurheartj/ehu272
44. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M, Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008 359 473 481. doi: 10.1056/NEJMoa071142
45. O'Donoghue ML, Glaser R, Aylward PE, Cavender MA, Crisp A, Fox KA, Laws I, Lopez-Sendon JL, Steg PG, Theroux P, Sabatine MS, Morrow DA, Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. Am Heart J 2015 169 622 630.e6. doi: 10.1016/j.ahj.2015.02.012
46. Bagai A, Schulte PJ, Granger CB, Mahaffey KW, Christenson RH, Bell G, Lopes RD, Green CL, Lincoff AM, Armstrong PW, Roe MT, Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. Am Heart J 2014 168 503 511.e2. doi: 10.1016/j.ahj.2014.06.008
47. Kim HW, Farzaneh-Far A, Kim RJ, Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications. J Am Coll Cardiol 2009 55 1 16. doi: 10.1016/j.jacc.2009.06.059